Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Daiichi Sankyo
Fuji
Teva
Citi
US Department of Justice
Medtronic
UBS
Healthtrust

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202379

« Back to Dashboard

NDA 202379 describes ZYTIGA, which is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ZYTIGA profile page.

The generic ingredient in ZYTIGA is abiraterone acetate. There are twenty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abiraterone acetate profile page.
Summary for 202379
Tradename:ZYTIGA
Applicant:Janssen Biotech
Ingredient:abiraterone acetate
Patents:2
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 202379
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZYTIGA abiraterone acetate TABLET;ORAL 202379 NDA Janssen Biotech, Inc. 57894-150 57894-150-25 120 TABLET in 1 BOTTLE (57894-150-25)
ZYTIGA abiraterone acetate TABLET;ORAL 202379 NDA Janssen Biotech, Inc. 57894-150 57894-150-12 120 TABLET in 1 BOTTLE (57894-150-12)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength250MG
Approval Date:Apr 28, 2011TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Dec 13, 2016Product Flag?YSubstance Flag?YDelist Request?
Patented Use:USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Patent:➤ SubscribePatent Expiration:Dec 13, 2016Product Flag?YSubstance Flag?YDelist Request?
Patented Use:USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
Patent:➤ SubscribePatent Expiration:Aug 24, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Accenture
Chinese Patent Office
US Army
QuintilesIMS
Medtronic
Farmers Insurance
Fuji
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot